Epoetin beta for the treatment of chemotherapy-induced anemia: an update

OncoTargets and Therapy
Luca GalliColin Gerard Egan

Abstract

Epoetin beta belongs to the class of erythropoiesis-stimulating agents (ESAs) that are currently available to treat anemic patients receiving chemotherapy. Chemotherapy-induced anemia affects a high percentage of cancer patients and, due to its negative effects on disease outcome and the patient's quality of life, should be treated when first diagnosed. Initial trials with ESAs have shown efficacy in improving quality of life and reducing the need for blood transfusions in patients with chemotherapy-induced anemia. However, recent meta-analyses have provided conflicting data on the impact of ESAs on survival and tumor progression. Here we provide an overview of these recent data and review the role of epoetin beta in the treatment of chemotherapy-induced anemia over the past 20 years.

Citations

Feb 18, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Francesco SaccàAlessandro Filla

❮ Previous
Next ❯

Software Mentioned

BRAVE
NAUTICA

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

© 2021 Meta ULC. All rights reserved